Additional Therapeutic Areas

Imaging in Personalized Medicine Trials

Imaging biomarkers targeting molecular pathways provide actionable data on patient heterogeneity. By visualizing molecular target distribution and activity—such as amyloid plaque burden in Alzheimer’s disease—imaging biomarkers enable precise patient stratification and dynamic monitoring of drug efficacy. This is crucial for addressing population variability.

Perceptive integrates these biomarkers into trials, allowing sponsors to optimize dosing, refine inclusion criteria, and predict therapeutic responses, ultimately supporting the development of tailored treatments for diverse populations.

RTSM in Personalized Medicine Trials

Our randomization and trial supply experts ensure the right patient receives the right treatment at the right time—essential for managing complex, patient-led supply chains, rapid timeframes, gene and stem cell preservation, and complicated visit management schedules per personalized treatment plans.

Imaging in Vaccine Trials

Our preclinical imaging team supports the development of mRNA vaccines by visualizing and quantifying mRNA delivery, expression, and immune responses. Using advanced imaging modalities such as bioluminescence, fluorescence, and molecular PET/CT, we track the biodistribution and stability of mRNA constructs in vivo. These imaging biomarkers enable precise assessment of delivery and immune activation dynamics over time.

RTSM in Vaccine Trials

Our RTSM design experts can ensure you meet the unique and pressing timelines of vaccine clinical trials by providing proven IRT functionality that helps you meet fast-paced recruitment levels, optimize site supplies tailored to the season, and adapt quickly to mid-trail changes.

At Perceptive, we offer comprehensive expertise in supporting cardiovascular (CV) clinical trials. Our team specializes in leveraging advanced and complex imaging modalities, including echocardiography, cardiac MRI, CT angiography, MUGA, and cardiac scintigraphy, to assess eligibility, efficacy, and safety endpoints. 

We utilize industry-leading medical imaging software applications powered by AI technology for the independent review and analysis of highly complex imaging data. We have a proven track record of success in supporting numerous clinical trials across a range of disease indications, particularly in rare diseases including Hypertrophic Obstructive Cardiomyopathy (HOCM), Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM), Fabry disease, and Friedreich Ataxia Cardiomyopathy. 

Our end-to-end process ensures seamless support, from site qualification to final data delivery, to drive the success of your CV clinical trials.

Perceptive supports gastrointestinal studies across many indications, imaging modalities, and approaches including but not limited to:

-Magnetic Resonance Imaging including anatomical and specialized sequences to support indications such as Crohn’s disease, ulcerative colitis, and metabolic non-acholic steatohepatitis (MASH)

-Abdominal ultrasound for qualitative and quantitative liver, biliary, and Doppler assessments

-Endoscopy and colonoscopy video imaging for eosinophilic esophagitis, eosinophilic duodenitis, and ulcerative colitis studies

The scientific and operational teams at Perceptive have collaborated with key opinion leaders and experienced reader groups to support the unique imaging requirements of your trial. We have in-house expertise and have provided end-to-end imaging services on more than 50 clinical trials. 

Perceptive is at the forefront of recent advancements in pulmonary imaging assessments. Partnering with leaders in data-driven texture analysis (DTA) and other AI-based assessments, Perceptive can provide solutions for objective, reproducible analysis in Idiopathic Pulmonary Fibrosis (IPF) and Chronic Sinusitis.      

Providing precise guidance on the acquisition of HRCT, the Perceptive team ensures that quantitative data analysis is of the highest quality, allowing for accurate assessment of disease severity and identification of key biomarkers. 

Our experienced reviewers, who have read thousands of images for more than 80 clinical trials, also provide qualitative assessments for indications such as Asthma, Chronic Obstructive Pulmonary Disease, Human Respiratory Syncytial Virus, and Pulmonary Sarcoidosis. Perceptive can support every step in the process of acquiring the valuable data needed for the success of your clinical trial.  

Perceptive has managed over 55 trials with ophthalmology imaging in support of both efficacy and safety endpoints, with extensive experience across all study phases in multiple therapeutic areas. 

Perceptive has gained deep expertise in understanding the challenges associated with ocular imaging and functional testing, with the expertise and capability to deliver imaging and testing solutions for anterior segment to posterior pole, tear film to visual cortex. 

Whether standard photo protocols, ultrasound, MRI, or novel modalities, Perceptive utilizes different workflows in support of partnerships with reading centers, academic labs, and independent ophthalmologist readers. 

Perceptive has significant experience and expertise in the measurement of organ volumes on images acquired using different imaging modalities including CT, MRI, and ultrasound. 

Perceptive has supported the assessment of volumes of organs such as the spleen, liver, kidney, lung, uterus, muscle, brain, and heart across a variety of indications. 

Volumetric analysis is not restricted to organ measurements only—Perceptive has the capability to perform volume measurements of sub-anatomical structures (e.g. hippocampal volume in the brain) and abnormal tissue on images such as volume of fibrotic lung in diseases such as Idiopathic Lung